Ischemic Stroke Market

• Increasing prevalence of ischemic stroke globally is expected to boost market growth

The rising global prevalence of ischemic stroke is projected to drive ischemic stroke market growth. This is owing to an increase in the incidence of ischemic stroke, which is being ascribed to a variety of factors including an ageing population, sedentary lifestyles, bad eating habits, and the rising prevalence of risk factors such as hypertension, diabetes, and obesity. Furthermore, developments in medical technologies and treatment alternatives are projected to fuel market expansion.

For instance, as per the 2021 Heart Disease & Stroke Statistical Update Fact Sheet provided by the American Heart Association, the global prevalence of stroke in 2019 was 101.5 million people, while that of ischemic stroke was 77.2 million. Overall, age-standardized stroke prevalence rate in 2019 was highest in Oceania, Southeast Asia, North Africa, and the Middle East, as well as East Asia. 

Countries in parts of North Africa and the Middle East, Southern sub-Saharan Africa, high-income countries in North America and Southeast Asia had the highest ischemic stroke prevalence rate. Furthermore, in 2019, there were 6.6 million deaths worldwide due to cerebrovascular diseases. In 2019, a total of 3.3 million people worldwide died from ischemic stroke, 2.9 million died from intracerebral hemorrhage, and 0.4 million died from subarachnoid hemorrhage.

These factors are projected to fuel Ischemic Stroke market revenue expansion in the next years and improve market CAGR across the globe in the recent years.

The increasing geriatric population worldwide is a crucial driver of the Global Ischemic Stroke Market Industry. Older adults are at a higher risk of experiencing ischemic strokes due to age-related factors such as vascular changes and comorbidities. As the global population ages, the demand for stroke prevention and treatment services is anticipated to rise. This demographic shift is projected to influence market dynamics significantly, with the Global Ischemic Stroke Market expected to witness a compound annual growth rate of 7.13 percent from 2025 to 2035. The implications of this trend are profound, as healthcare systems must adapt to meet the needs of an aging population.

Growing awareness regarding the symptoms and risk factors associated with ischemic stroke is driving the Global Ischemic Stroke Market Industry. Public health campaigns and educational initiatives have been instrumental in informing individuals about the importance of early recognition and intervention. This heightened awareness encourages individuals to seek medical attention promptly, thereby increasing the demand for diagnostic and therapeutic services. As a result, healthcare systems are likely to allocate more resources towards stroke management, further propelling market growth. The emphasis on education and awareness is expected to play a crucial role in shaping the future landscape of the Global Ischemic Stroke Market.

Technological innovations in medical devices and treatment methodologies are significantly influencing the Global Ischemic Stroke Market Industry. The development of advanced imaging techniques, such as CT and MRI, enhances the ability to diagnose ischemic strokes promptly. Furthermore, the introduction of minimally invasive surgical techniques and novel thrombolytic agents has improved patient outcomes. These advancements not only facilitate timely interventions but also contribute to the overall growth of the market. As the industry adapts to these technological changes, it is likely that the Global Ischemic Stroke Market will continue to expand, potentially reaching 10.5 USD Billion by 2035.

Government initiatives aimed at reducing the incidence of ischemic stroke are pivotal to the Global Ischemic Stroke Market Industry. Various countries are implementing stroke prevention programs and allocating funding for research and development of new treatment options. These initiatives not only enhance healthcare infrastructure but also promote collaboration among stakeholders in the medical community. By investing in public health strategies and supporting clinical trials, governments are likely to foster innovation in stroke care. This commitment to improving health outcomes is expected to contribute significantly to the market's growth trajectory over the coming years.

The increasing incidence of ischemic stroke globally is a primary driver of the Global Ischemic Stroke Market Industry. According to health statistics, ischemic strokes account for approximately 87 percent of all strokes, leading to a growing demand for effective treatment options. As populations age and lifestyle-related risk factors such as hypertension and diabetes become more prevalent, the burden of ischemic stroke is expected to rise. This trend is reflected in the market's projected growth, with the Global Ischemic Stroke Market anticipated to reach 4.92 USD Billion in 2024. Such figures underscore the urgent need for innovative therapies and preventive measures.

By Region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. North America Ischemic Stroke market dominated in 2022, followed by Europe and the Asia-Pacific. North America Ischemic Stroke dominated the market owing to favorable government initiatives, technical breakthroughs, and increased demand for ischemic stroke solutions. 

Furthermore, prominent market players are focusing on inorganic growth tactics such as acquisitions and partnerships to expand their product portfolio and presence in the worldwide acute ischemic stroke (AIS) market. For example, AstraZeneca, a global, science-led biopharmaceutical company, announced the November 2020 launch of Brilinta (an oral, reversible, direct-acting P2Y12 receptor antagonist), which is used to reduce the risk of stroke in patients with acute ischemic stroke or high-risk transient ischemic attack (TIA).

Furthermore, the rising occurrence of stroke in North America propels market expansion. According to the American Heart Association 2022, cardiovascular disease (CVD) was acknowledged as the leading cause of death in the United States in 2019, accounting for 874,613 fatalities. Furthermore, according to Dawn O. Kleindorfer's research published in the American Heart Association Journal in May 2021, 795 000 people in the United States have a stroke each year, with 87% (690 000) being ischemic and 185 000 being recurrent. Almost 240,000 people suffer from a transient ischemic stroke each year (TIA).

As a result, the country's rising prevalence of cardiovascular illnesses and stroke is likely to drive the acute ischemic stroke diagnosis market.

Further, the major countries studied in the market report are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: ISCHEMIC STROKE MARKET SHARE BY REGION 2022 (%)

Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

The European ischemic stroke market accounts for a sizable portion of the worldwide market of Ischemic Stroke. Europe has a big and ageing population that is predisposed to ischemic stroke due to variables such as hypertension, high cholesterol, diabetes, and smoking. The European ischemic stroke market is predicted to increase at a CAGR of 5.2% from 2024 to 2030. The region's increasing frequency of ischemic stroke, combined with a growing awareness of the need of early diagnosis and treatment, is likely to fuel market growth.

Further, the Germany market of Ischemic Stroke held the largest market share, and the UK market of Ischemic Stroke was the fastest growing market in the European region

The Asia-Pacific ischemic stroke market is expanding as a result of a number of factors, including rising ischemic stroke incidence and prevalence, improved healthcare infrastructure and treatment availability, and rising healthcare expenditure in the region. The Asia-Pacific area is rapidly ageing, with several countries expecting a substantial share of senior citizens in the future decades. Because age is a major risk factor for ischemic stroke, this demographic shift has been connected to an increased incidence of the disorder. 

Furthermore, the region is seeing an increase in lifestyle-related risk factors such hypertension, diabetes, and smoking, which raises the risk of ischemic stroke. Moreover, the region's growing healthcare infrastructure and availability to treatment are fueling market expansion. Many Asian countries are actively investing in their healthcare systems, which has resulted in increased diagnosis and treatment capacities. 

Furthermore, the increased availability of advanced medical technologies such as CT and MRI scanners, as well as an increase in the number of stroke centers and neurologists, has made it simpler for patients to receive early and effective treatment. Moreover, China market of Ischemic Stroke held the largest market share, and the India market of Ischemic Stroke was the fastest growing market in the Asia-Pacific region.

The market of Ischemic Stroke is highly competitive, with several major market players operating in the market. Market participants are also pursuing a variety of market developments to expand their global footprint, including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other companies. Competitors in the Ischemic Stroke industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

The Ischemic Stroke market major player such as Fujifilm Holdings Corporation, Samsung Electronics Co. Ltd, GE Healthcare, Siemens Healthcare, Kohden Corporation, Koninklijke Philips NV, and Others.

Fujifilm Holdings Company is a Japanese multinational conglomerate headquartered in Tokyo. The company operates in a variety of industries, including imaging, information solutions, and document solutions. Fujifilm's portfolio includes healthcare-related products and services such as medical imaging equipment, diagnostics, and regenerative medicine. Fujifilm provides a variety of goods and services for the diagnosis and treatment of ischemic stroke in the market. 

Medical imaging equipment from the company, such as the Synapse Picture Archiving and Communication System (PACS), is utilised for the visualisation and processing of brain pictures, which can aid in the diagnosis and management of ischemic stroke. Fujifilm also provides ischemic stroke diagnostic instruments, such as the FCT Embrace and FDR Go PLUS computed tomography (CT) scanners.

GE Healthcare is a multinational conglomerate headquartered in Chicago, Illinois, United States. The company is a major provider of medical technologies and solutions, focusing on improving healthcare outcomes through advanced diagnostic and therapeutic products. GE Healthcare provides a variety of products and services for the diagnosis and treatment of ischemic stroke in the market. Medical imaging technology from the company, such as its Optima CT and Discovery MR scanners, can help with the diagnosis of ischemic stroke by providing detailed images of the brain. 

GE Healthcare also provides a variety of diagnostic tools for ischemic stroke, such as their CT Perfusion software, which can assist clinicians in determining the extent of brain damage caused by a stroke in a timely and accurate manner.